Jerome Stevens' $1.3 Bil. Levothyroxine Suit Against FDA Dismissed
This article was originally published in The Pink Sheet Daily
D.C. federal court rules that FDA acted within its authority to extend the deadline to review levothyroxine products. Damage from FDA's release of confidential information related to Jerome Stevens' Unithroid NDA was not demonstrated to be separate from that of the deadline extension.
You may also be interested in...
Generics should demonstrate same dose consistency as 505(b)(2) applications, the company says. Jerome Stevens requests guidance clarifying ANDA review standards and asks FDA to consider pulling Mylan’s Unithroid generic.
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability
Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said